Literature DB >> 1776557

Intrauterine devices in nulliparous women.

K R Petersen1, L Brooks, B Jacobsen, S O Skouby.   

Abstract

The majority of studies on the clinical events following the insertion of an intrauterine device for contraception have observed a higher frequency of adverse effects in nulliparous women. In this review, the significance of nulliparity on the occurrence of medical removal for bleeding and pain, expulsion and pelvic inflammatory disease is estimated. The possible role of the anatomy of the pregravid uterus is discussed, and results obtained through a selective measurement of the endometrial cavity in a population of nulligravidas is presented. It is concluded that IUDs should not be the first choice of contraception in nulliparous women because of an increased risk of long-term adverse effects. The relationship between the length of the intrauterine device and the length of the endometrial cavity does not seem to be of clinical significance for the performance of IUDs in nulliparous women.

Entities:  

Mesh:

Year:  1991        PMID: 1776557     DOI: 10.1007/bf02340179

Source DB:  PubMed          Journal:  Adv Contracept        ISSN: 0267-4874


  3 in total

1.  Precision intrauterine contraception may significantly increase continuation of use: a review of long-term clinical experience with frameless copper-releasing intrauterine contraception devices.

Authors:  Dirk Wildemeersch; Ansgar Pett; Sohela Jandi; Thomas Hasskamp; Patrick Rowe; Marc Vrijens
Journal:  Int J Womens Health       Date:  2013-04-30

2.  Increasing access to intrauterine contraceptive device uptake in Ghana: stakeholders views on task sharing service delivery with community health nurses.

Authors:  Fred Y Gbagbo; Emmanuel Sk Morhe
Journal:  Ghana Med J       Date:  2020-06

Review 3.  A review of barriers and myths preventing the more widespread use of intrauterine contraception in nulliparous women.

Authors:  Kirsten Black; Pamela Lotke; Kai J Buhling; Nikki B Zite
Journal:  Eur J Contracept Reprod Health Care       Date:  2012-07-26       Impact factor: 1.848

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.